Biocon arm, Lupin get US FDA approval for dapagliflozin tablets
This story was originally published at 09:59 IST on 8 April 2026
Register to read our real-time news.Informist, Wednesday, Apr. 8, 2026
--Lupin gets US FDA approval for dapagliflozin tablets
--Biocon arm gets US FDA approval for dapagliflozin tablets
MUMBAI – Lupin Ltd. and Biocon Ltd.'s subsidiary Biocon Pharma Ltd. have received approval from the US Food and Drug Administration for dapagliflozin tablets. Dapagliflozin tablets are used to treat Type-II diabetes and heart diseases. Lupin's dapagliflozin tablets are bioequivalent to Farxiga, the company said in an exchange filing.
At 0940 IST, shares of Lupin traded slightly higher at INR 2,309.70 apiece on the National Stock Exchange and those of Biocon were up nearly 2% at INR 346.40. For the December quarter, Lupin reported a consolidated net profit of INR 11.76 billion on revenues of INR 71.68 billion. Biocon reported a consolidated net profit of INR 1.44 billion on revenues of INR 41.73 billion. End
IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT
Reported by Prateem Rohankear
Edited by Avishek Dutta
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
